<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00469690</url>
  </required_header>
  <id_info>
    <org_study_id>5305</org_study_id>
    <nct_id>NCT00469690</nct_id>
  </id_info>
  <brief_title>Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects</brief_title>
  <official_title>Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovative Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovative Medical</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the ability of two different topical NSAIDs
      (non-steroidal anti-inflammatory medications used for pain relief) to reach the back of the
      eye and to stop inflammation. The study will conclude on the day of your cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aqueous concentrations</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PGE2 Inhibition</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acular, Xibrom</intervention_name>
    <description>Acular 5ml (in the eye)Instill one drop into the eye to be operated on four times a day at (6am, 12pm, 6pm, 12am)
Xibrom 5ml (in the eye) Instill one drop into the eye to be operated on two times a day (8am and 8pm)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy Male/Female 21 years of age of older.

          2. Patient understands and is willing to sign the written informed consent form

          3. Likely to complete the entire course of the study.

          4. Patient is scheduled to undergo cataract surgery

          5. Female patients of childbearing potential must have had a regular menstrual cycle
             prior to study entry (a female is considered of childbearing potential unless she is
             postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal
             ligation).

          6. Patient is willing and able to administer eye drops and record the times the drops
             were instilled

        Exclusion Criteria:

          1. Patient has been using a topical NSAID within 1 week of study entry

          2. Patient has a known sensitivity to any of the ingredients in the study medications

          3. Patient has sight in only one eye

          4. Patient has a history of previous intraocular surgery

          5. Patient's doctor has determined they have a condition (i.e., UNCONTROLLED systemic
             disease) or are in a situation that may put them at significant risk, confound the
             study results or may interfere significantly with their participation in the study

          6. Female patients who are pregnant, nursing an infant or planning a pregnancy

          7. Patients who are currently involved in another investigational study or have
             participated in one within the 30 days prior to entering this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Bucci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bucci Laser Vision Institute and Ambulatory Surgery Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bucci Laser Vision Institute and Ambulatory Surgery Center</name>
      <address>
        <city>Wilkes Barre</city>
        <state>Pennsylvania</state>
        <zip>18702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2007</study_first_posted>
  <last_update_submitted>May 19, 2008</last_update_submitted>
  <last_update_submitted_qc>May 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Frank Bucci, MD</name_title>
    <organization>Bucci Laser Vision Institute and Ambulatory Surgery Cneter</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Bromfenac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

